Neogen Co. (NASDAQ:NEOG) Director Jack C. Parnell sold 2,418 shares of the company’s stock in a transaction on Friday, August 10th. The shares were sold at an average price of $83.97, for a total value of $203,039.46. Following the completion of the transaction, the director now owns 14,073 shares of the company’s stock, valued at $1,181,709.81. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

NEOG stock opened at $83.89 on Friday. Neogen Co. has a 12-month low of $48.55 and a 12-month high of $84.99. The stock has a market cap of $4.33 billion, a price-to-earnings ratio of 69.33 and a beta of 1.33.

Neogen (NASDAQ:NEOG) last posted its quarterly earnings results on Tuesday, July 17th. The company reported $0.33 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.30 by $0.03. Neogen had a return on equity of 11.97% and a net margin of 15.70%. The firm had revenue of $109.29 million during the quarter, compared to the consensus estimate of $108.11 million. During the same quarter in the previous year, the business earned $0.24 earnings per share. The firm’s quarterly revenue was up 10.6% compared to the same quarter last year. equities research analysts forecast that Neogen Co. will post 1.27 EPS for the current year.

A number of hedge funds have recently bought and sold shares of the business. Granahan Investment Management Inc. MA purchased a new stake in Neogen during the second quarter valued at about $283,000. MetLife Investment Advisors LLC grew its position in Neogen by 3.9% during the second quarter. MetLife Investment Advisors LLC now owns 22,979 shares of the company’s stock valued at $1,843,000 after acquiring an additional 861 shares during the period. Tower Research Capital LLC TRC purchased a new stake in Neogen during the second quarter valued at about $106,000. Cubist Systematic Strategies LLC purchased a new stake in Neogen during the second quarter valued at about $642,000. Finally, First Republic Investment Management Inc. grew its position in Neogen by 14.3% during the second quarter. First Republic Investment Management Inc. now owns 6,986 shares of the company’s stock valued at $560,000 after acquiring an additional 874 shares during the period. 89.58% of the stock is owned by hedge funds and other institutional investors.

Several equities analysts recently commented on NEOG shares. Craig Hallum upped their target price on Neogen from $65.00 to $70.00 and gave the company a “hold” rating in a research note on Wednesday, July 18th. Zacks Investment Research lowered Neogen from a “hold” rating to a “sell” rating in a research note on Thursday, May 31st. BidaskClub upgraded Neogen from a “buy” rating to a “strong-buy” rating in a research note on Friday, June 15th. Finally, ValuEngine upgraded Neogen from a “buy” rating to a “strong-buy” rating in a research note on Friday, July 6th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $67.75.

Neogen Company Profile

Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment primarily offers diagnostic test kits and complementary to detect dangerous and/or unintended substances in human food and animal feed, such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test for adenosine triphosphate, a chemical found in living cells.

Read More: Dividend

Insider Buying and Selling by Quarter for Neogen (NASDAQ:NEOG)

Receive News & Ratings for Neogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neogen and related companies with MarketBeat.com's FREE daily email newsletter.